Financing ·
China SXT terminates $12M over-allotment option for registered direct offering
SXTCChina SXT Pharmaceuticals, Inc.
China SXT Pharmaceuticals has entered into a termination letter agreement to fully terminate the additional purchase right (over-allotment option) associated with its registered direct offering announced on October 8, 2026. This right had permitted investors to acquire up to an additional $12 million of Class A ordinary shares and pre-funded warrants within 30 days of the initial closing. The termination means purchasers no longer have any entitlement to make these additional purchases, though all other provisions of the original securities purchase agreement remain in full force. The company operates as an innovative pharmaceutical firm focusing on the research, development, manufacture, marketing, and sales of traditional Chinese medicine pieces.